ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
DSM plans a June start-up for its cGMP biologic drugs facility in Brisbane, Australia. Built with cooperation from local and national government agencies, the 500-kg-per-year facility will be Australia’s first custom mammalian-cell-based biopharmaceutical plant. Separately, DSM has signed an agreement to manufacture a therapeutic antibody for Cambridge, Mass.-based DecImmune Therapeutics. Initial development will take place in DSM’s plant in Groningen, the Netherlands; manufacturing of clinical trial material would occur at the new Australian site.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter